S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94

Corbus Pharmaceuticals (CRBP) Stock Forecast, Price & News

+0.00 (+2.05%)
(As of 05/13/2022 06:55 PM ET)
Today's Range
50-Day Range
52-Week Range
5.06 million shs
Average Volume
1.14 million shs
Market Capitalization
$26.84 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive CRBP News and Ratings via Email

Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Corbus Pharmaceuticals logo

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$880 thousand
Book Value
$0.55 per share


Net Income
$-45.64 million
Net Margins
Pretax Margin




Free Float
Market Cap
$26.84 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.05 out of 5 stars

Medical Sector

507th out of 1,403 stocks

Pharmaceutical Preparations Industry

225th out of 667 stocks

Analyst Opinion: 3.2Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Corbus Pharmaceuticals (NASDAQ:CRBP) Frequently Asked Questions

Is Corbus Pharmaceuticals a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Corbus Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRBP, but not buy additional shares or sell existing shares.
View analyst ratings for Corbus Pharmaceuticals
or view top-rated stocks.

When is Corbus Pharmaceuticals' next earnings date?

Corbus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Corbus Pharmaceuticals

How were Corbus Pharmaceuticals' earnings last quarter?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) issued its earnings results on Tuesday, May, 10th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.01. Corbus Pharmaceuticals had a negative net margin of 2,856.56% and a negative trailing twelve-month return on equity of 52.32%.
View Corbus Pharmaceuticals' earnings history

What price target have analysts set for CRBP?

3 Wall Street analysts have issued 12-month price targets for Corbus Pharmaceuticals' shares. Their forecasts range from $2.00 to $3.00. On average, they expect Corbus Pharmaceuticals' stock price to reach $2.50 in the next twelve months. This suggests a possible upside of 1,066.6% from the stock's current price.
View analysts' price targets for Corbus Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Corbus Pharmaceuticals' key executives?
Corbus Pharmaceuticals' management team includes the following people:
  • Dr. Yuval Cohen Ph.D., CEO & Director (Age 47, Pay $846.92k)
  • Mr. Sean F. Moran CPA, M.B.A., CPA, MBA, Chief Financial Officer (Age 64, Pay $542k)
  • Mr. Craig Stuart Millian M.B.A., Chief Operating Officer (Age 53, Pay $542k)
  • Dr. Rachael Brake Ph.D., Chief Scientific Officer (Age 50)
  • Ted Jenkins, Sr. Director of Investor Relations & Corp. Communications
  • Ms. Lindsey Smith, Head of Corp. Communications & Patient Advocacy
  • Ms. Christina Bertsch, Head of HR
  • Scott Constantine, Sr. Director & Head of Clinical Operations
What other stocks do shareholders of Corbus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Matinas BioPharma (MTNB), (CGC), Inovio Pharmaceuticals (INO) and KushCo (KSHB).

What is Corbus Pharmaceuticals' stock symbol?

Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."

Who are Corbus Pharmaceuticals' major shareholders?

Corbus Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.43%), Mirae Asset Global Investments Co. Ltd. (3.00%), Renaissance Technologies LLC (0.92%), Pinnacle Associates Ltd. (0.73%), GSA Capital Partners LLP (0.41%) and Davy Global Fund Management Ltd (0.35%). Company insiders that own Corbus Pharmaceuticals stock include Craig Stuart Millian, Sean F Moran and Yuval Cohen.
View institutional ownership trends for Corbus Pharmaceuticals

Which major investors are selling Corbus Pharmaceuticals stock?

CRBP stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Mirae Asset Global Investments Co. Ltd., Simplex Trading LLC, Pinnacle Associates Ltd., and Group One Trading L.P..
View insider buying and selling activity for Corbus Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Corbus Pharmaceuticals stock?

CRBP stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, GSA Capital Partners LLP, and Davy Global Fund Management Ltd. Company insiders that have bought Corbus Pharmaceuticals stock in the last two years include Craig Stuart Millian, Sean F Moran, and Yuval Cohen.
View insider buying and selling activity for Corbus Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Corbus Pharmaceuticals?

Shares of CRBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Corbus Pharmaceuticals' stock price today?

One share of CRBP stock can currently be purchased for approximately $0.21.

How much money does Corbus Pharmaceuticals make?

Corbus Pharmaceuticals has a market capitalization of $26.84 million and generates $880 thousand in revenue each year. The biopharmaceutical company earns $-45.64 million in net income (profit) each year or ($0.33) on an earnings per share basis.

How many employees does Corbus Pharmaceuticals have?

Corbus Pharmaceuticals employs 41 workers across the globe.

What is Corbus Pharmaceuticals' official website?

The official website for Corbus Pharmaceuticals is www.corbuspharma.com.

How can I contact Corbus Pharmaceuticals?

Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company can be reached via phone at (617) 963-0100, via email at [email protected], or via fax at 617-663-6085.

This page was last updated on 5/16/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.